Výsledky vyhledávání - "Elliot M Antman"

Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial

Autor: Siddharth M Patel, Michael G Palazzolo, Sabina A Murphy, Elliot M Antman, Eugene Braunwald, Hans-Joachim Lanz, Gregory Y H Lip, Robert P Giugliano, Christian T Ruff

Publikováno v: Patel, S M, Palazzolo, M G, Murphy, S A, Antman, E M, Braunwald, E, Lanz, H J, Lip, G Y H, Giugliano, R P & Ruff, C T 2022, ' Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial ', Europace, vol. 24, no. 11, pp. 1730-1738 . https://doi.org/10.1093/europace/euac082

Aims The Atrial fibrillation Better Care (ABC) pathway is endorsed by guidelines to improve care of patients with atrial fibrillation (AF). However, whether the benefit of ABC pathway-concordant care is consistent across anticoagulants remains unclea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20d7b75f0ff65294905557fd557c71eb
https://pubmed.ncbi.nlm.nih.gov/36017608

Zobrazit plný text záznamu

Serial measurement of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48

Autor: David A. Morrow, Elliot M Antman, H Lanz, Sabina A. Murphy, Minao Tang, David D. Berg, Kazuma Oyama, Michael A. Grosso, Christian T. Ruff, E Braunwald, Robert P. Giugliano

Publikováno v: European Heart Journal. 41

Background Patients with atrial fibrillation (AF) have progressive cardiac structural changes that may be manifest by biomarkers of myocardial injury and hemodynamic stress. Baseline values of hsTnT (high-sensitivity troponin T), and NT-proBNP (N-ter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1cb5b7d318c22681e87a13512b6818ca
https://doi.org/10.1093/ehjci/ehaa946.0512

Zobrazit plný text záznamu

Is there a role for half-dose anticoagulation in atrial fibrillation? Randomized comparison of 2 doses of edoxaban in 14,014 patients in ENGAGE AF-TIMI 48

Autor: Jeong-Gun Park, E Braunwald, Elliot M Antman, Sabina A. Murphy, Christian T. Ruff, Robert P. Giugliano, Jan Steffel

Publikováno v: European Heart Journal. 41

Background In the phase 3 RCT ENGAGE AF-TIMI 48, both the higher-dose (HDER/edoxaban 60/30mg) and lower-dose edoxaban regimen (LDER/edoxaban 30/15mg) were non-inferior to well-managed warfarin for the prevention of stroke or systemic embolic events i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ba76e329fdcfd7ce4669d72f03f97b72
https://doi.org/10.1093/ehjci/ehaa946.0659

Zobrazit plný text záznamu

Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor

Autor: Megan L. Neely, Sonia Huang, Lars Wallentin, Michelle T. Sun, Christopher X. Wong, Elliot M Antman, E. Magnus Ohman, Matthew T. Roe, Stephen D. Wiviott

Publikováno v: The American journal of cardiology. 125(8)

Intraocular bleeding is a devastating clinical event due to its potentially blinding nature. It is not known if determine if dual antiplatelet therapy using aspirin and potent P2Y12 inhibitors increases this risk. We searched MEDLINE and ClinicalTria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d364a58e0b2c8c9220c7d0b935c80fc3
https://pubmed.ncbi.nlm.nih.gov/32081368

Zobrazit plný text záznamu

P3526Heart Failure hospitalization and mortality in non-valvular Atrial Fibrillation: The ENGAGE-AF TIMI 48 Trial

Autor: Christian T. Ruff, Robert P. Giugliano, Howard Rutman, Elliot M Antman, Scott D. Solomon, E Braunwald, Riccardo M. Inciardi, Francesco Nordio

Publikováno v: European Heart Journal. 40

Introduction Atrial Fibrillation (AF) is associated with increased risk of cardiovascular (CV) morbidity and mortality. Heart Failure (HF) represents the most common CV complication, more common than thromboembolic events. Purpose We aimed to determi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2b2a65ca77ceac022748d4f067a08b09
https://doi.org/10.1093/eurheartj/ehz745.0390

Zobrazit plný text záznamu

460Edoxaban versus warfarin in atrial fibrillation patients with low, mid and high body weight: analysis of outcomes in the engage AF TIMI 48 trial

Autor: E Braunwald, Julia F Kuder, Christian T. Ruff, G Boriani, Robert P. Giugliano, Minggao Shi, Elliot M Antman, H Lanz

Publikováno v: European Heart Journal. 40

Background The impact on outcomes of oral anticoagulants in pts at extremes of body weight have not been well-characterized. Aim To analyse the outcomes of pts with atrial fibrillation (AF) enrolled in ENGAGE AF-TMI 48 randomized to warfarin (W) targ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::53cea383362a2cd755b69913c0d69914
https://doi.org/10.1093/eurheartj/ehz747.0119

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání